| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | 0.0092 | 0.8 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | 0.0091 | 0.8 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.0084 | 0.8 |
| mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.0075 | 0.8 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | 0.0084 | 0.8 |
| mRNA | AZD-7545 | CTRPv2 | pan-cancer | AAC | -0.0087 | 0.8 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.8 |
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.8 |